CN106957270A - 一种硝基尿嘧啶药物超分子共晶及其制备方法 - Google Patents

一种硝基尿嘧啶药物超分子共晶及其制备方法 Download PDF

Info

Publication number
CN106957270A
CN106957270A CN201710181534.2A CN201710181534A CN106957270A CN 106957270 A CN106957270 A CN 106957270A CN 201710181534 A CN201710181534 A CN 201710181534A CN 106957270 A CN106957270 A CN 106957270A
Authority
CN
China
Prior art keywords
supermolecule
medicine
nitrouracil
eutectic
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201710181534.2A
Other languages
English (en)
Other versions
CN106957270B (zh
Inventor
李星
田园园
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hebei Dahe Biological Technology Co ltd
Original Assignee
Ningbo University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ningbo University filed Critical Ningbo University
Priority to CN201710181534.2A priority Critical patent/CN106957270B/zh
Publication of CN106957270A publication Critical patent/CN106957270A/zh
Application granted granted Critical
Publication of CN106957270B publication Critical patent/CN106957270B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/127—Preparation from compounds containing pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/22—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing two or more pyridine rings directly linked together, e.g. bipyridyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyridine Compounds (AREA)

Abstract

本发明公开了一种硝基尿嘧啶药物超分子共晶及其制备方法，该超分子共晶是一种具有确定空间结构的5‑硝基尿嘧啶和4,4’‑二联吡啶的超分子共晶化合物，其分子式为C18H14N8O8，结构单元为[(C10H8N2)(C4H3N3O4)2]，晶系为三斜晶系，空间群为P‑1，晶胞参数为α＝97.373°，β＝101.803°，γ＝105.339°。所述超分子共晶的制备方法为：将具有共轭大π键的4,4’‑二联吡啶、5‑硝基乳清酸钾与具有催化活性的钴离子按一定的比例混合进行化学反应，制得一种超分子共晶。该制备方法操作简单，成本低廉，适合规模化生产。本发明制备的超分子共晶化合物作为药物或药物中间体具有潜在的应用前景。

Description

一种硝基尿嘧啶药物超分子共晶及其制备方法
技术领域
本发明属于超分子化学领域，具体涉及一种硝基尿嘧啶药物超分子共晶及其制备方法。
背景技术
超分子化学的诞生使化学的发展进入了革命性的新时代，其发展十分迅猛，因为超分子具有与其组成分子不同的物理、化学和生物性质，一般都具有特殊的用途，如用作导体、光学材料、纳米材料、传感器等。超分子化学涉及到的领域十分广泛，它不仅涉及无机化学、有机化学、配位化学、高分子化学和药物化学，而且涉及材料科学、环境科学、信息科学和生命科学。超分子化学的发展标志着化学走进了一个崭新的研究领域。
随着超分子化学研究的深入，超分子化学在药物研发领域的延伸成为化学发展的一个重要分支。药物超分子逐渐成为国内外学者共同关注的一个研究热点。药物超分子具有许多优点，如低的药物毒性、良好的稳定性、较高的安全性。药物超分子化学是一个新兴交叉学科并逐渐成为一个独立的研究领域。到目前为止，已经有许多药物超分子作为化学药物在临床上使用，事实表明其疗效非常好，还有许多作为候选药物的超分子化合物正在进行临床的实验和研究开发。
目前，嘧啶环系化合物在医药方面的应用受到生物界、化学界和医学界的关注，如5-甲基嘧啶是遗传物质的重要组成部分，是合成抗艾滋病药物AZT、DDT及相关药物的关键中间体，也是合成抗肿瘤、抗病毒药物β-胸苷的起始原料；5-氟脲嘧啶是一种阻止肿瘤细胞嘧啶类核苷酸形成的抗代谢药物。
然而，人们研究发现一些嘧啶类药物具有半衰期短、选择性差、稳定性差、生物利用度低、药溶性差、副作用大等弱点，限制了其广泛应用。因此，人们试图对嘧啶化合物进行各种化学修饰，力求找到一种低毒、利用高效的嘧啶类化合物，并以此作为抗癌药物的先导化合物。
近年来研究发现药物超分子共晶能够提高药物的利用度、改善药物的溶解度或药物活性。因此，对药物超分子共晶的研究引起了人们的极大兴趣。
本发明以水合醋酸钴、联吡啶和硝基乳清酸为原料，通过简单的水热反应，制备了一种硝基尿嘧啶和联吡啶的超分子共晶化合物，该化合物具有确定的空间结构和准确的分子式，分子中存在多种非典型的氢键(C—H···O： )和π-π作用这些结构信息对本发明获得的硝基尿嘧啶药物超分子共晶化合物的性能研究和应用具有重要的意义。
发明内容
本发明所要解决的技术问题是针对现有技术，提供一种硝基尿嘧啶药物超分子共晶及其制备方法。
本发明为解决上述技术问题所采取的技术方案为：一种硝基尿嘧啶药物超分子共晶，该超分子共晶是一种5-硝基尿嘧啶和4,4’-二联吡啶的超分子共晶化合物，该化合物具有确定的空间结构，结构单元为[(C10H8N2)(C4H3N3O4)2]，其分子式为C18H14N8O8，晶系为三斜晶系，空间群为P-1，晶胞参数为 α＝97.373°，β＝101.803°，γ＝105.339°。
一种上述硝基尿嘧啶药物超分子共晶的制备方法，包括以下步骤：
(1)向25mL聚四氟乙烯内衬中加入适量的5-硝基乳清酸钾单水合物、4,4’-二联吡啶和水合氯化钴，然后加入蒸馏水5～10mL和体积分数95％的乙醇5～8mL，搅拌，得反应混合物；
(2)将上述聚四氟乙烯内衬密封，放入不锈钢反应釜中，将不锈钢反应釜放入烘箱中，120～150℃加热反应48～72h，然后自然冷却至室温，打开反应釜得浅黄色块状晶体；
(3)将浅黄色块状晶体取出，自然风干，即得所述的超分子共晶。
优选的，所述参加反应的物质均为化学纯，所述水合氯化钴为六水氯化钴。
较佳地，所述5-硝基乳清酸钾单水合物、4,4’-二联吡啶和水合氯化钴的摩尔比为2∶1∶1～2。
与现有技术相比，本发明的特点在于：
将具有共轭π键的4,4’-二联吡啶、5-硝基乳清酸钾与具有化学催化活性的钴离子进行化学反应，在化学反应中5-硝基乳清酸脱去羧基成为5-硝基尿嘧啶，并与4,4’-二联吡啶进行自组装，制得一种联吡啶与硝基尿嘧啶的超分子共晶化合物，该化合物具有准确的空间结构(图1)和准确的分子式，分子中存在多种非典型的氢键(C—H···O：)和π-π作用所制备的超分子共晶化合物作为药物或药物中间体具有潜在的应用前景。
附图说明
图1为本发明的超分子共晶化合物结构单元图。
具体实施方式
以下结合实施例对本发明作进一步详细描述。
实施例1：
向25mL聚四氟乙烯内衬中加入5-硝基乳清酸钾单水合物(1.0mmol，0.257g)，4,4’-二联吡啶(0.5mmol，0.0781g)，和CoCl2·6H2O(0.5mmol，0.119g)，并加蒸馏水10mL和体积分数95％的乙醇5mL，搅拌，得反应混合物；将聚四氟乙烯内衬密封，放入不锈钢反应釜中，将不锈钢反应釜放入烘箱中，150℃加热反应48h，然后自然冷却至室温，打开反应釜得浅黄色块状晶体；取出浅黄色块状晶体，自然风干，即得所述的超分子共晶化合物。
实施例2：
向25mL聚四氟乙烯内衬中加入5-硝基乳清酸钾单水合物(0.2mmol，0.0514g)，4,4’-二联吡啶(0.1mmol，0.0156g)，和CoCl2·6H2O(0.2mmol，0.0476g)，并加蒸馏水5mL和体积分数95％的乙醇8mL，搅拌，得反应混合物；将聚四氟乙烯内衬密封，放入不锈钢反应釜中，将不锈钢反应釜放入烘箱中，120℃加热反应72h，然后自然冷却至室温，打开反应釜得浅黄色块状晶体；取出浅黄色块状晶体，自然风干，即得所述的超分子共晶化合物。
实施例3：
向25mL聚四氟乙烯内衬中加入5-硝基乳清酸钾单水合物(0.2mmol，0.0514g)，4,4’-二联吡啶(0.1mmol，0.0156g)，和CoCl2·6H2O(0.15mmol，0.0357g)，并加蒸馏水7mL和体积分数95％的乙醇7mL，搅拌，得反应混合物；将聚四氟乙烯内衬密封，放入不锈钢反应釜中，将不锈钢反应釜放入烘箱中，130℃加热反应60h，然后自然冷却至室温，打开反应釜得浅黄色块状晶体；取出浅黄色块状晶体，自然风干，即得所述的超分子共晶化合物。
将实施例1-3制得的浅黄色块状晶体用单晶X射线进行结构测试，结果表明该浅黄色块状晶体为5-硝基尿嘧啶和4,4’-二联吡啶的超分子共晶化合物，其结构单元如图1所示，其分子式为C18H14N8O8，结构单元为[(C10H8N2)(C4H3N3O4)2]，晶系为三斜晶系，空间群为P-1，晶胞参数为 α＝97.373°，β＝101.803°，γ＝105.339°。

Claims (4)

1.一种硝基尿嘧啶药物超分子共晶，其特征在于，该超分子共晶是一种具有确定空间结构的5-硝基尿嘧啶和4,4’-二联吡啶的超分子共晶化合物，其分子式为C18H14N8O8，结构单元为[(C10H8N2)(C4H3N3O4)2]，晶系为三斜晶系，空间群为P-1，晶胞参数为α＝97.373°，β＝101.803°，γ＝105.339°。
2.一种如权利要求1所述的硝基尿嘧啶药物超分子共晶的制备方法，其特征在于，包括以下步骤：
(1)向25mL聚四氟乙烯内衬中加入适量的5-硝基乳清酸钾单水合物、4,4’-二联吡啶和水合氯化钴，然后加入蒸馏水5～10mL和体积分数95％的乙醇5～8mL，搅拌，得反应混合物；
(2)将上述聚四氟乙烯内衬密封，放入不锈钢反应釜中，将不锈钢反应釜放入烘箱中，120～150℃加热反应48～72h，然后自然冷却至室温，打开反应釜得浅黄色块状晶体；
(3)将浅黄色块状晶体取出，自然风干，即得所述的超分子共晶。
3.根据权利要求2所述的硝基尿嘧啶药物超分子共晶的制备方法，其特征在于，所述5-硝基乳清酸钾单水合物、4,4’-二联吡啶和水合氯化钴的摩尔比为2∶1∶1～2。
4.根据权利要求2所述的硝基尿嘧啶药物超分子共晶的制备方法，其特征在于，所述参加反应的物质均为化学纯，所述水合氯化钴为六水氯化钴。
CN201710181534.2A 2017-03-24 2017-03-24 一种硝基尿嘧啶药物超分子共晶及其制备方法 Active CN106957270B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710181534.2A CN106957270B (zh) 2017-03-24 2017-03-24 一种硝基尿嘧啶药物超分子共晶及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710181534.2A CN106957270B (zh) 2017-03-24 2017-03-24 一种硝基尿嘧啶药物超分子共晶及其制备方法

Publications (2)

Publication Number Publication Date
CN106957270A true CN106957270A (zh) 2017-07-18
CN106957270B CN106957270B (zh) 2019-05-24

Family

ID=59470470

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710181534.2A Active CN106957270B (zh) 2017-03-24 2017-03-24 一种硝基尿嘧啶药物超分子共晶及其制备方法

Country Status (1)

Country Link
CN (1) CN106957270B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108676020A (zh) * 2018-05-08 2018-10-19 宁波大学 一种硝基尿嘧啶铜超分子化合物及其制备方法
CN110372880A (zh) * 2019-08-01 2019-10-25 淮阴师范学院 一种可用于二维码防伪的有机超分子光致变色化合物及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102153552A (zh) * 2011-03-01 2011-08-17 吉林大学 两种新型帕潘立酮药物共晶及其制备方法
CN103113361A (zh) * 2013-03-06 2013-05-22 吉林三善恩科技开发有限公司 一种伊潘立酮-糖精有机药物共晶及其制备方法
CN104557732A (zh) * 2014-12-16 2015-04-29 哈尔滨医科大学 5-氟尿嘧啶药物共晶及其制备方法和应用
CN105330606A (zh) * 2015-11-04 2016-02-17 哈尔滨医科大学 2-氨基吡啶为前驱体的5-氟尿嘧啶药物共晶及其制备方法和应用
CN105732517A (zh) * 2016-02-01 2016-07-06 哈尔滨医科大学 包含烟酰胺为前驱体的5-氟尿嘧啶药物共晶的药物制剂及其制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102153552A (zh) * 2011-03-01 2011-08-17 吉林大学 两种新型帕潘立酮药物共晶及其制备方法
CN103113361A (zh) * 2013-03-06 2013-05-22 吉林三善恩科技开发有限公司 一种伊潘立酮-糖精有机药物共晶及其制备方法
CN104557732A (zh) * 2014-12-16 2015-04-29 哈尔滨医科大学 5-氟尿嘧啶药物共晶及其制备方法和应用
CN105330606A (zh) * 2015-11-04 2016-02-17 哈尔滨医科大学 2-氨基吡啶为前驱体的5-氟尿嘧啶药物共晶及其制备方法和应用
CN105732517A (zh) * 2016-02-01 2016-07-06 哈尔滨医科大学 包含烟酰胺为前驱体的5-氟尿嘧啶药物共晶的药物制剂及其制备方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108676020A (zh) * 2018-05-08 2018-10-19 宁波大学 一种硝基尿嘧啶铜超分子化合物及其制备方法
CN110372880A (zh) * 2019-08-01 2019-10-25 淮阴师范学院 一种可用于二维码防伪的有机超分子光致变色化合物及其制备方法
CN110372880B (zh) * 2019-08-01 2022-01-11 淮阴师范学院 一种可用于二维码防伪的有机超分子光致变色化合物及其制备方法

Also Published As

Publication number Publication date
CN106957270B (zh) 2019-05-24

Similar Documents

Publication Publication Date Title
CN101503423A (zh) 一种对氯苯甲酰腙有机锡配合物及制备方法与应用
CN109651189B (zh) 一种苯甲酰腙类神经氨酸酶抑制剂及其制备方法和用途
CN106957270B (zh) 一种硝基尿嘧啶药物超分子共晶及其制备方法
Li et al. Rapid incorporation of a difluoroacetate radical into para-quinone methides via radical 1, 6-conjugate addition
CN104530056B (zh) 一种邻萘醌与四唑并嘧啶的杂合体及其合成方法
Li et al. Highly enantio-and diastereoselective synthesis of α-trifluoromethyldihydropyrans using a novel bifunctional piperazine-thiourea catalyst
CN101955480B (zh) 一种吡唑并[3,4-b]喹啉化合物及其制备方法
CN103570768A (zh) 一种钴氮配合物
CN101475583B (zh) 一种二丁基二氯化锡schiff碱配位化合物及其制备方法与应用
CN101768182B (zh) 有机锡酰腙配合物及其制备方法与应用
Zhang et al. Two novel salts of tris (hydroxymethyl) aminomethane (THAM): Synthesis, crystal structure, thermal and Hirshfeld surfaces analysis
Bahrin et al. Nitrogen-Based Linkers with a Mesitylene Core: Synthesis and Characterization
CN106316936B (zh) 一种镉氨力农荧光材料及其制备方法
CN108676020A (zh) 一种硝基尿嘧啶铜超分子化合物及其制备方法
Cheng et al. Manipulating Reaction Energy Coordinate Landscape of Mechanochemical Diaza-Cope Rearrangement
CN111718326B (zh) 一种含喹啉结构的nnn型嘧啶腙钴(ii)配合物及其制备方法和应用
CN110981771A (zh) 一种甲磺司特工艺杂质e制备方法及用途
CN102643262B (zh) 一种8-乙氧基-2-(对氟苯基)-3-硝基-2h-苯并吡喃的制备方法
CN106986899A (zh) 一种伊马替尼超分子化合物及其制备方法
CN105481944B (zh) 一种苯并咪唑衍生物二肽铜配合物及其制备方法和应用
CN104530062B (zh) 一种1,4-萘醌衍生物及其合成方法
CN101747384B (zh) 5-氯水杨酰肼三苯基锡配位化合物及其制备方法与应用
CN109535098B (zh) 一种用于黏度检测的近红外荧光探针及其制备和应用
CN106966937A (zh) 二芳基硒醚类衍生物及其制备方法
CN103319493B (zh) 一种合成1-羟甲基-3-氢-2-氧杂金刚烷及其衍生物的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220802

Address after: Room 2202, 22 / F, Wantong building, No. 3002, Sungang East Road, Sungang street, Luohu District, Shenzhen City, Guangdong Province

Patentee after: Shenzhen dragon totem technology achievement transformation Co.,Ltd.

Address before: 315211, Fenghua Road, Jiangbei District, Zhejiang, Ningbo 818

Patentee before: Ningbo University

Effective date of registration: 20220802

Address after: 052360 Xinji high tech Industrial Development Zone, Shijiazhuang City, Hebei Province

Patentee after: HEBEI DAHE BIOLOGICAL TECHNOLOGY CO.,LTD.

Address before: Room 2202, 22 / F, Wantong building, No. 3002, Sungang East Road, Sungang street, Luohu District, Shenzhen City, Guangdong Province

Patentee before: Shenzhen dragon totem technology achievement transformation Co.,Ltd.